Legal & General Group Plc Decreases Stock Position in Teleflex Incorporated $TFX

Legal & General Group Plc lessened its position in Teleflex Incorporated (NYSE:TFX) by 15.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,797 shares of the medical technology company’s stock after selling 20,554 shares during the quarter. Legal & General Group Plc’s holdings in Teleflex were worth $13,888,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Banque Cantonale Vaudoise lifted its position in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Teleflex in the third quarter valued at approximately $35,000. V Square Quantitative Management LLC purchased a new position in Teleflex during the fourth quarter worth approximately $37,000. Finally, Sound Income Strategies LLC purchased a new position in Teleflex during the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Price Performance

TFX stock opened at $125.29 on Wednesday. The business has a fifty day moving average of $125.28 and a two-hundred day moving average of $117.54. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of -5.50, a price-to-earnings-growth ratio of 0.95 and a beta of 0.82. Teleflex Incorporated has a 52-week low of $100.18 and a 52-week high of $139.67.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts anticipate that Teleflex Incorporated will post 6.7 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, May 22nd. This represents a $1.36 annualized dividend and a yield of 1.1%. Teleflex’s dividend payout ratio (DPR) is -5.96%.

Analyst Ratings Changes

A number of brokerages recently commented on TFX. Bank of America upgraded Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a research report on Monday, April 13th. Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Friday, March 27th. Royal Bank Of Canada upgraded Teleflex from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday, May 8th. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teleflex currently has a consensus rating of “Hold” and a consensus target price of $144.00.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.